Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

More good news came  from Exelixis (EXEL). It was expected by many but not by those who …

Exelixis collaborator, Daiichi Sankyo, Receives Regulatory Approval for MINNEBRO™ (Esaxerenone) Tablets for Hypertension in Japan Exelixis …

Earlier this month the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CTX001 for …

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focused on the development and commercialization of therapeutics for …

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

Gilead Sciences (GILD) and Scholar Rock Holding Corporation (SRRK) announced entering into a strategic collaboration to discover and develop …

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD). …

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s …